

Appl. No. 10/526,822  
Reply to Office Action of November 16, 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A clear ophthalmic solution comprising latanoprost having a concentration of 0.005 to 0.01% (W/V) as an active ingredient and benzalkonium chloride as a preservative wherein white turbidity due to a change of formulation is prevented by at least one means selected from the following 1) to 3);

1) adding a surfactant,

2) using benzalkonium chloride represented by the formula of  $[C_6H_5CH_2N(CH_3)_2R]Cl$  (wherein R is alkyl having 12 carbon atoms) as the preservative and

3) adding a nonionic tonicity agent.

2. (Currently amended) The ophthalmic solution as claimed in claim 1, wherein ~~a latanoprost concentration is 0.001 to 0.01%~~

Appl. No. 10/526,822  
Reply to Office Action of November 16, 2006

~~(W/V)~~, and a benzalkonium chloride concentration is 0.003 to 0.01% (W/V).

3. (Currently amended) The ophthalmic solution as claimed in claim 9 ~~claim 1~~, wherein the surfactant is Polysorbate 80, polyoxyethylene hydrogenated castor oil 60, polyoxyl 35 castor oil or polyethylene glycol monostearate.

4. (Currently amended) The ophthalmic solution as claimed in claim 9 ~~claim 1~~, wherein the nonionic tonicity agent is glycerin, mannitol, polyethylene glycol, propylene glycol, trehalose or sucrose.

5. (Currently amended) A method of preventing white turbidity due to a change of formulation in an ophthalmic solution comprising latanoprost having a concentration of 0.005 to 0.01% (W/V) as an active ingredient and benzalkonium chloride as a preservative by at least one means selected from the following 1) to 3);

1) adding a surfactant,

Appl. No. 10/526,822

Reply to Office Action of November 16, 2006

2) using benzalkonium chloride represented by the formula of  $[C_6H_5CH_2N(CH_3)_2R]Cl$  (wherein R is alkyl having 12 carbon atoms) as the preservative and

3) adding a nonionic tonicity agent.

6. (Original) The method of preventing white turbidity as claimed in claim 5, wherein a benzalkonium chloride concentration is 0.003 to 0.01% (W/V).

7. (Currently amended) The method of preventing white turbidity as claimed in claim 10 ~~claim 5~~, wherein the surfactant is Polysorbate 80, polyoxyethylene hydrogenated castor oil 60, polyoxyl 35 castor oil or polyethylene glycol monostearate.

8. (Original) The method of preventing white turbidity as claimed in claim 7 ~~claim 5~~, wherein the nonionic tonicity agent is glycerin, mannitol, polyethylene glycol, propylene glycol, trehalose or sucrose.

Appl. No. 10/526,822

Reply to Office Action of November 16, 2006

9. (New) The ophthalmic solution as claimed in claim 2, wherein a latanoprost concentration is 0.005% (W/V).

10. (New) The method of preventing white turbidity as claimed in claim 6, wherein a latanoprost concentration is 0.005% (W/V).